share_log

Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5

Benzinga ·  Jun 14 14:42

Ladenburg Thalmann analyst Matthew Kaplan maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $48 to $53.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment